APA (7th ed.) Citation

LM, A., LP, L., NAS, O., RFO, S., B, S., J, B., . . . JMA, O. (2026). The PERK inhibitor GSK2606414 evokes developmental defects in zebrafish consistent with Wolcott-Rallison syndrome phenotypes. Pharmacological reports : PR, 78(2), 487. https://doi.org/10.1007/s43440-026-00837-7

Chicago Style (17th ed.) Citation

LM, Almeida, Lima LP, Oliveira NAS, Silva RFO, Sousa B, Bessa J, Pinho BR, and Oliveira JMA. "The PERK Inhibitor GSK2606414 Evokes Developmental Defects in Zebrafish Consistent with Wolcott-Rallison Syndrome Phenotypes." Pharmacological Reports : PR 78, no. 2 (2026): 487. https://doi.org/10.1007/s43440-026-00837-7.

MLA (9th ed.) Citation

LM, Almeida, et al. "The PERK Inhibitor GSK2606414 Evokes Developmental Defects in Zebrafish Consistent with Wolcott-Rallison Syndrome Phenotypes." Pharmacological Reports : PR, vol. 78, no. 2, 2026, p. 487, https://doi.org/10.1007/s43440-026-00837-7.